Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma

James W Freeman, P. McGrath, V. Bondada, N. Selliah, H. Ownby, T. Maloney, R. K. Busch, H. Busch

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Nucleolar antigen P120 is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of P120 in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for P120; 114 of these tumors were also stained for the erbB-2 protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine % (83 of 120) of the tumors were positive for P120; 25% (28 of 114) stained positively for erbB-2. Of the 28 erbB-2 positive tumors 26 were also positive for the P120 protein. Forty-six % (55 of 120) of the specimens were from patients who later died from recurrent breast cancer; P120 was detected in 89% (49 of 55) of these specimens. In 52% of the survivors the P120 protein was also expressed. P120 negative tumors were highly correlative with survival (P = 0.0001); 84% (32 of 37) of patients with P120 negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed P120 (P = 0.0001); death occurred in 73% (30 of 41) of these patients. For the node negative patients who did not express P120, 5-year survival was 90% (19 of 21 patients); 5-year survival for the node negative patients who expressed P120 was significantly less (67%; 28 of 42 patients). Patients with P120 negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86% (18 of 21) and for those with positive nodes survival was 82% (13 of 16). A poor prognosis was found for patients with intense erbB-2 stained tumors (5 of 7 patients died). Weak staining of erbB-2 tumors (21 specimens) was not correlated with patient survival. Compared to P120 negative tumors, P120 positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of P120 positive tumors was greater in estrogen receptor positive tumors (75%) than in estrogen negative tumors (54%). These studies suggest that antigen P120 may be a prognostic marker in breast cancer and could be used along with other parameters such as nodal status to assess the prognostic outcome of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)1973-1978
Number of pages6
JournalCancer Research
Volume51
Issue number8
StatePublished - Apr 15 1991
Externally publishedYes

Fingerprint

Breast Neoplasms
Antigens
Neoplasms
Survival
Mitosis
Estrogen Receptors
Staining and Labeling
Proteins
Survivors
Estrogens
Multivariate Analysis
Retrospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Freeman, J. W., McGrath, P., Bondada, V., Selliah, N., Ownby, H., Maloney, T., ... Busch, H. (1991). Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Research, 51(8), 1973-1978.

Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. / Freeman, James W; McGrath, P.; Bondada, V.; Selliah, N.; Ownby, H.; Maloney, T.; Busch, R. K.; Busch, H.

In: Cancer Research, Vol. 51, No. 8, 15.04.1991, p. 1973-1978.

Research output: Contribution to journalArticle

Freeman, JW, McGrath, P, Bondada, V, Selliah, N, Ownby, H, Maloney, T, Busch, RK & Busch, H 1991, 'Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma', Cancer Research, vol. 51, no. 8, pp. 1973-1978.
Freeman JW, McGrath P, Bondada V, Selliah N, Ownby H, Maloney T et al. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Research. 1991 Apr 15;51(8):1973-1978.
Freeman, James W ; McGrath, P. ; Bondada, V. ; Selliah, N. ; Ownby, H. ; Maloney, T. ; Busch, R. K. ; Busch, H. / Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. In: Cancer Research. 1991 ; Vol. 51, No. 8. pp. 1973-1978.
@article{e21788cafd274a7ab7206d1712a0737b,
title = "Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma",
abstract = "Nucleolar antigen P120 is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of P120 in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for P120; 114 of these tumors were also stained for the erbB-2 protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine {\%} (83 of 120) of the tumors were positive for P120; 25{\%} (28 of 114) stained positively for erbB-2. Of the 28 erbB-2 positive tumors 26 were also positive for the P120 protein. Forty-six {\%} (55 of 120) of the specimens were from patients who later died from recurrent breast cancer; P120 was detected in 89{\%} (49 of 55) of these specimens. In 52{\%} of the survivors the P120 protein was also expressed. P120 negative tumors were highly correlative with survival (P = 0.0001); 84{\%} (32 of 37) of patients with P120 negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed P120 (P = 0.0001); death occurred in 73{\%} (30 of 41) of these patients. For the node negative patients who did not express P120, 5-year survival was 90{\%} (19 of 21 patients); 5-year survival for the node negative patients who expressed P120 was significantly less (67{\%}; 28 of 42 patients). Patients with P120 negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86{\%} (18 of 21) and for those with positive nodes survival was 82{\%} (13 of 16). A poor prognosis was found for patients with intense erbB-2 stained tumors (5 of 7 patients died). Weak staining of erbB-2 tumors (21 specimens) was not correlated with patient survival. Compared to P120 negative tumors, P120 positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of P120 positive tumors was greater in estrogen receptor positive tumors (75{\%}) than in estrogen negative tumors (54{\%}). These studies suggest that antigen P120 may be a prognostic marker in breast cancer and could be used along with other parameters such as nodal status to assess the prognostic outcome of breast cancer patients.",
author = "Freeman, {James W} and P. McGrath and V. Bondada and N. Selliah and H. Ownby and T. Maloney and Busch, {R. K.} and H. Busch",
year = "1991",
month = "4",
day = "15",
language = "English (US)",
volume = "51",
pages = "1973--1978",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma

AU - Freeman, James W

AU - McGrath, P.

AU - Bondada, V.

AU - Selliah, N.

AU - Ownby, H.

AU - Maloney, T.

AU - Busch, R. K.

AU - Busch, H.

PY - 1991/4/15

Y1 - 1991/4/15

N2 - Nucleolar antigen P120 is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of P120 in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for P120; 114 of these tumors were also stained for the erbB-2 protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine % (83 of 120) of the tumors were positive for P120; 25% (28 of 114) stained positively for erbB-2. Of the 28 erbB-2 positive tumors 26 were also positive for the P120 protein. Forty-six % (55 of 120) of the specimens were from patients who later died from recurrent breast cancer; P120 was detected in 89% (49 of 55) of these specimens. In 52% of the survivors the P120 protein was also expressed. P120 negative tumors were highly correlative with survival (P = 0.0001); 84% (32 of 37) of patients with P120 negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed P120 (P = 0.0001); death occurred in 73% (30 of 41) of these patients. For the node negative patients who did not express P120, 5-year survival was 90% (19 of 21 patients); 5-year survival for the node negative patients who expressed P120 was significantly less (67%; 28 of 42 patients). Patients with P120 negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86% (18 of 21) and for those with positive nodes survival was 82% (13 of 16). A poor prognosis was found for patients with intense erbB-2 stained tumors (5 of 7 patients died). Weak staining of erbB-2 tumors (21 specimens) was not correlated with patient survival. Compared to P120 negative tumors, P120 positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of P120 positive tumors was greater in estrogen receptor positive tumors (75%) than in estrogen negative tumors (54%). These studies suggest that antigen P120 may be a prognostic marker in breast cancer and could be used along with other parameters such as nodal status to assess the prognostic outcome of breast cancer patients.

AB - Nucleolar antigen P120 is detected in rapidly proliferating cells but not in normal resting cells or in many benign and slowly growing malignant tumors. The objective of the study was to determine whether the expression of P120 in breast cancer correlated with histopathological or biological properties associated with prognosis. In this retrospective study, 120 primary breast tumors were analyzed for P120; 114 of these tumors were also stained for the erbB-2 protein. Immunopositive staining was correlated with patient survival, nodal status, estrogen receptor levels, and number of mitoses. Sixty-nine % (83 of 120) of the tumors were positive for P120; 25% (28 of 114) stained positively for erbB-2. Of the 28 erbB-2 positive tumors 26 were also positive for the P120 protein. Forty-six % (55 of 120) of the specimens were from patients who later died from recurrent breast cancer; P120 was detected in 89% (49 of 55) of these specimens. In 52% of the survivors the P120 protein was also expressed. P120 negative tumors were highly correlative with survival (P = 0.0001); 84% (32 of 37) of patients with P120 negative tumors survived more than 7 years without evidence of recurrent disease. Multivariate analysis showed that the worst prognosis was for patients who had tumor positive nodes and expressed P120 (P = 0.0001); death occurred in 73% (30 of 41) of these patients. For the node negative patients who did not express P120, 5-year survival was 90% (19 of 21 patients); 5-year survival for the node negative patients who expressed P120 was significantly less (67%; 28 of 42 patients). Patients with P120 negative tumors had a good prognosis, irrespective of their nodal status. In this group, survival of node negative patients was 86% (18 of 21) and for those with positive nodes survival was 82% (13 of 16). A poor prognosis was found for patients with intense erbB-2 stained tumors (5 of 7 patients died). Weak staining of erbB-2 tumors (21 specimens) was not correlated with patient survival. Compared to P120 negative tumors, P120 positive tumors had greater numbers of mitoses (9.06 versus 6.65) and an almost 2-fold increase in the occurrence of positive nodes (one of every 4.67 versus one of every 8.81). The number of P120 positive tumors was greater in estrogen receptor positive tumors (75%) than in estrogen negative tumors (54%). These studies suggest that antigen P120 may be a prognostic marker in breast cancer and could be used along with other parameters such as nodal status to assess the prognostic outcome of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0025783072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025783072&partnerID=8YFLogxK

M3 - Article

C2 - 1672621

AN - SCOPUS:0025783072

VL - 51

SP - 1973

EP - 1978

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -